

# Maria Shipkova

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/8995783/maria-shipkova-publications-by-year.pdf>

**Version:** 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

96  
papers

3,896  
citations

35  
h-index

60  
g-index

102  
ext. papers

4,434  
ext. citations

3.9  
avg, IF

4.96  
L-index

#	Paper	IF	Citations
96	Therapeutic Drug Monitoring of Antibiotic Drugs: The Role of the Clinical Laboratory. <i>Therapeutic Drug Monitoring</i> , <b>2021</b> ,	3.2	2
95	Personalized Therapy for Mycophenolate: Consensus Report by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. <i>Therapeutic Drug Monitoring</i> , <b>2021</b> , 43, 150-200	3.2	17
94	The Impact of on Tacrolimus Pharmacokinetics and Outcome in Clinical Practice at a Single Kidney Transplant Center. <i>Frontiers in Genetics</i> , <b>2019</b> , 10, 871	4.5	10
93	Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report. <i>Therapeutic Drug Monitoring</i> , <b>2019</b> , 41, 261-307	3.2	163
92	Pharmacokinetic and Pharmacodynamic Drug Monitoring of Direct-Acting Oral Anticoagulants: Where Do We Stand?. <i>Therapeutic Drug Monitoring</i> , <b>2019</b> , 41, 180-191	3.2	14
91	Measurement of sirolimus concentrations in human blood using an automated electrochemiluminescence immunoassay (ECLIA): a multicenter evaluation. <i>Clinical Chemistry and Laboratory Medicine</i> , <b>2018</b> , 56, 764-775	5.9	5
90	Validation of a high-performance liquid chromatography method for thiopurine S-methyltransferase activity in whole blood using 6-mercaptopurine as substrate. <i>Clinical Chemistry and Laboratory Medicine</i> , <b>2018</b> , 56, 803-809	5.9	2
89	Multicenter Evaluation of a New Electrochemiluminescence Immunoassay for Everolimus Concentrations in Whole Blood. <i>Therapeutic Drug Monitoring</i> , <b>2018</b> , 40, 59-68	3.2	3
88	Therapeutic Drug Monitoring of Everolimus: Comparability of Concentrations Determined by 2 Immunoassays and a Liquid Chromatography Tandem Mass Spectrometry Method. <i>Therapeutic Drug Monitoring</i> , <b>2017</b> , 39, 102-108	3.2	11
87	Optimizing everolimus exposure when combined with calcineurin inhibitors in solid organ transplantation. <i>Transplantation Reviews</i> , <b>2017</b> , 31, 151-157	3.3	16
86	Pharmacokinetics and Clinical Outcomes of Generic Tacrolimus (Hexal) Versus Branded Tacrolimus in De Novo Kidney Transplant Patients: A Multicenter, Randomized Trial. <i>Transplantation</i> , <b>2017</b> , 101, 2780-2788	1.8	7
85	Lymphocyte surface molecules as immune activation biomarkers. <i>Clinical Biochemistry</i> , <b>2016</b> , 49, 347-54	3.5	24
84	Simultaneous determination of mycophenolate and its metabolite mycophenolate-7-o-glucuronide with an isocratic HPLC-UV-based method in human plasma and stability evaluation. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , <b>2016</b> , 76, 612-619	2	4
83	Analytical Validation and Cross-Validation of an NFAT-Regulated Gene Expression Assay for Pharmacodynamic Monitoring of Therapy With Calcineurin Inhibitors. <i>Therapeutic Drug Monitoring</i> , <b>2016</b> , 38, 711-716	3.2	7
82	LC-MS/MS as a tool for TDM services: Where are we?. <i>Clinical Biochemistry</i> , <b>2016</b> , 49, 1009-23	3.5	46
81	T-Cell Surface Antigens and sCD30 as Biomarkers of the Risk of Rejection in Solid Organ Transplantation. <i>Therapeutic Drug Monitoring</i> , <b>2016</b> , 38 Suppl 1, S29-35	3.2	1
80	Liquid chromatography tandem mass spectrometry for therapeutic drug monitoring of immunosuppressive drugs: Achievements, lessons and open issues. <i>TrAC - Trends in Analytical Chemistry</i> , <b>2016</b> , 84, 23-33	14.6	17

79	Biomarker monitoring in immunosuppressant therapy <b>2016</b> , 125-152		1
78	Comparing the effect of isotopically labeled or structural analog internal standards on the performance of a LC-MS/MS method to determine ciclosporin A, everolimus, sirolimus and tacrolimus in whole blood. <i>Clinical Chemistry and Laboratory Medicine</i> , <b>2016</b> , 54, 437-46	5.9	12
77	Barcelona Consensus on Biomarker-Based Immunosuppressive Drugs Management in Solid Organ Transplantation. <i>Therapeutic Drug Monitoring</i> , <b>2016</b> , 38 Suppl 1, S1-20	3.2	57
76	Analytical Aspects of the Implementation of Biomarkers in Clinical Transplantation. <i>Therapeutic Drug Monitoring</i> , <b>2016</b> , 38 Suppl 1, S80-92	3.2	5
75	Performance of a phosphoflow assay to determine phosphorylation of S6 ribosomal protein as a pharmacodynamic read out for mTOR inhibition. <i>Clinical Biochemistry</i> , <b>2016</b> , 49, 1181-1187	3.5	5
74	Therapeutic Drug Monitoring of Everolimus: A Consensus Report. <i>Therapeutic Drug Monitoring</i> , <b>2016</b> , 38, 143-69	3.2	71
73	Analytical evaluation of a real-time PCR-based DNA demethylation assay to assess the frequency of naturally occurring regulatory T cells in peripheral blood. <i>Clinical Biochemistry</i> , <b>2016</b> , 49, 1173-1180	3.5	1
72	Assuring the Proper Analytical Performance of Measurement Procedures for Immunosuppressive Drug Concentrations in Clinical Practice: Recommendations of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology Immunosuppressive Drug Scientific Committee. <i>Therapeutic Drug Monitoring</i> , <b>2016</b> , 38, 176-89	3.2	65
71	Multi-center analytical evaluation of a novel automated tacrolimus immunoassay. <i>Clinical Biochemistry</i> , <b>2014</b> , 47, 1069-77	3.5	26
70	Comparability and imprecision of 8 frequently used commercially available immunoassays for therapeutic drug monitoring. <i>Therapeutic Drug Monitoring</i> , <b>2014</b> , 36, 433-41	3.2	22
69	Multicenter analytical evaluation of the automated electrochemiluminescence immunoassay for cyclosporine. <i>Therapeutic Drug Monitoring</i> , <b>2014</b> , 36, 640-50	3.2	19
68	CD26/dipeptidyl peptidase IV: a comparative study of healthy persons and kidney transplant recipients before and early after transplantation. <i>Clinical Biochemistry</i> , <b>2013</b> , 46, 1383-8	3.5	5
67	Improved method for therapeutic drug monitoring of 6-thioguanine nucleotides and 6-methylmercaptopurine in whole-blood by LC/MSMS using isotope-labeled internal standards. <i>Therapeutic Drug Monitoring</i> , <b>2013</b> , 35, 313-21	3.2	25
66	A randomized trial of intensified vs. standard dosing for enteric-coated mycophenolate sodium in de novo kidney transplant recipients: results at 1 year. <i>Clinical Nephrology</i> , <b>2013</b> , 79, 421-31	2.1	7
65	Pharmacokinetics and pharmacodynamics of mycophenolate sodium (EC-MPS) co-administered with cyclosporine in the early-phase post-kidney transplantation. <i>Clinical Transplantation</i> , <b>2012</b> , 26, 57-66	3.8	12
64	Surface markers of lymphocyte activation and markers of cell proliferation. <i>Clinica Chimica Acta</i> , <b>2012</b> , 413, 1338-49	6.2	113
63	Biomarkers: The Link between Therapeutic Drug Monitoring and Pharmacodynamics of Immunosuppressants <b>2012</b> , 349-372		0
62	The proton pump inhibitor pantoprazole and its interaction with enteric-coated mycophenolate sodium in transplant recipients. <i>Journal of Heart and Lung Transplantation</i> , <b>2011</b> , 30, 565-71	5.8	21

61	Safety and efficacy of intensified versus standard dosing regimens of enteric-coated mycophenolate sodium in de novo renal transplant patients. <i>Transplantation</i> , <b>2011</b> , 91, 779-85	1.8	24
60	Association between adverse effects under azathioprine therapy and inosine triphosphate pyrophosphatase activity in patients with chronic inflammatory bowel disease. <i>Therapeutic Drug Monitoring</i> , <b>2011</b> , 33, 321-8	3.2	34
59	Association between pharmacodynamic biomarkers and clinical events in the early phase after kidney transplantation: a single-center pilot study. <i>Therapeutic Drug Monitoring</i> , <b>2011</b> , 33, 341-9	3.2	13
58	Increased cyclosporine concentrations in the absence of cyclosporine administration. <i>Clinical Chemistry</i> , <b>2011</b> , 57, 670-3	5.5	11
57	Pharmacokinetics and pharmacodynamics of intensified versus standard dosing of mycophenolate sodium in renal transplant patients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , <b>2010</b> , 5, 503-11	6.9	36
56	Investigation of the crossreactivity of mycophenolic acid glucuronide metabolites and of mycophenolate mofetil in the Cedia MPA assay. <i>Therapeutic Drug Monitoring</i> , <b>2010</b> , 32, 79-85	3.2	24
55	Biomarkers as a tool for management of immunosuppression in transplant patients. <i>Therapeutic Drug Monitoring</i> , <b>2010</b> , 32, 560-72	3.2	46
54	The acyl glucuronide metabolite of mycophenolic acid induces tubulin polymerization in vitro. <i>Clinical Biochemistry</i> , <b>2010</b> , 43, 208-13	3.5	6
53	Bioavailability of mycophenolate mofetil and enteric-coated mycophenolate sodium is differentially affected by pantoprazole in healthy volunteers. <i>Journal of Clinical Pharmacology</i> , <b>2009</b> , 49, 1196-201	2.9	55
52	Clinical utility of therapeutic drug monitoring of mycophenolic acid in transplantation medicine: Where are we? / Der klinische Nutzen des Therapeutischen Drug Monitoring von Mycophenolsäure in der Transplantationsmedizin: Wo stehen wir?. <i>Laboratoriums Medizin</i> , <b>2009</b> , 33, 88-98		1
51	Irinotecan in cancer patients with end-stage renal failure. <i>Annals of Pharmacotherapy</i> , <b>2009</b> , 43, 363-9	2.9	14
50	Regulation of IL2 and NUCB1 in mononuclear cells treated with acyl glucuronide of mycophenolic acid reveals effects independent of inosine monophosphate dehydrogenase inhibition. <i>Therapeutic Drug Monitoring</i> , <b>2009</b> , 31, 31-41	3.2	3
49	Differential proteomic analysis of lymphocytes treated with mycophenolic acid reveals caspase 3-induced cleavage of rho GDP dissociation inhibitor 2. <i>Therapeutic Drug Monitoring</i> , <b>2009</b> , 31, 211-7	3.2	12
48	6-thioguanine nucleotide-adapted azathioprine therapy does not lead to higher remission rates than standard therapy in chronic active crohn disease: results from a randomized, controlled, open trial. <i>Clinical Chemistry</i> , <b>2007</b> , 53, 1306-14	5.5	81
47	Analysis of ITPA phenotype-genotype correlation in the Bulgarian population revealed a novel gene variant in exon 6. <i>Therapeutic Drug Monitoring</i> , <b>2007</b> , 29, 6-10	3.2	39
46	Proteins identified as targets of the acyl glucuronide metabolite of mycophenolic acid in kidney tissue from mycophenolate mofetil treated rats. <i>Biochimie</i> , <b>2007</b> , 89, 393-402	4.6	44
45	Measurement of erythrocyte inosine triphosphate pyrophosphohydrolase (ITPA) activity by HPLC and correlation of ITPA genotype-phenotype in a Caucasian population. <i>Clinical Chemistry</i> , <b>2006</b> , 52, 240-7 <sup>5</sup>	5.5	86
44	Glucuronidation in therapeutic drug monitoring. <i>Clinica Chimica Acta</i> , <b>2005</b> , 358, 2-23	6.2	45

43	Mycophenolate mofetil in organ transplantation: focus on metabolism, safety and tolerability. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2005</b> , 1, 505-26	5.5	70
42	Mycophenolic acid interaction with cyclosporine and tacrolimus in vitro and in vivo: evaluation of additive effects on rat blood lymphocyte function. <i>Therapeutic Drug Monitoring</i> , <b>2005</b> , 27, 123-31	3.2	18
41	Pharmacokinetics and bioavailability of mycophenolic acid after intravenous administration and oral administration of mycophenolate mofetil to heart transplant recipients. <i>Therapeutic Drug Monitoring</i> , <b>2005</b> , 27, 315-21	3.2	30
40	A Simple And Rapid High-performance Liquid Chromatographic Procedure for Determination Of Inosine 5??-monophosphate Dehydrogenase Activity in Isolated Human Mononuclear Blood Cells (Mbc). <i>Therapeutic Drug Monitoring</i> , <b>2005</b> , 27, 253	3.2	2
39	Association of inosine triphosphatase 94C>A and thiopurine S-methyltransferase deficiency with adverse events and study drop-outs under azathioprine therapy in a prospective Crohn disease study. <i>Clinical Chemistry</i> , <b>2005</b> , 51, 2282-8	5.5	74
38	Determination of thiopurine methyltransferase activity in isolated human erythrocytes does not reflect putative in vivo enzyme inhibition by sulfasalazine. <i>Clinical Chemistry</i> , <b>2004</b> , 50, 438-41	5.5	17
37	Validation of a rapid and sensitive liquid chromatography-tandem mass spectrometry method for free and total mycophenolic acid. <i>Clinical Chemistry</i> , <b>2004</b> , 50, 152-9	5.5	76
36	Identification of protein targets for mycophenolic acid acyl glucuronide in rat liver and colon tissue. <i>Proteomics</i> , <b>2004</b> , 4, 2728-38	4.8	44
35	Circulating cytokines as markers of systemic inflammatory response in severe community-acquired pneumonia. <i>Clinical Biochemistry</i> , <b>2004</b> , 37, 204-9	3.5	41
34	Synergistic effects of sirolimus with cyclosporine and tacrolimus: analysis of immunosuppression on lymphocyte proliferation and activation in rat whole blood. <i>Transplantation</i> , <b>2004</b> , 77, 1154-62	1.8	25
33	cDNA microarray analysis reveals new candidate genes possibly linked to side effects under mycophenolate mofetil therapy. <i>Transplantation</i> , <b>2004</b> , 78, 1145-52	1.8	15
32	Cyclosporin A absorption profiles in pediatric renal transplant recipients predict the risk of acute rejection. <i>Therapeutic Drug Monitoring</i> , <b>2004</b> , 26, 415-24	3.2	25
31	Analytic aspects of monitoring therapy with thiopurine medications. <i>Therapeutic Drug Monitoring</i> , <b>2004</b> , 26, 220-6	3.2	43
30	Therapie mit Thiopurin-Medikamenten TDM Und Pharmakogenomik der TPMT/Therapy with Thiopurine Drugs TDM and Pharmacogenomics of TPMT. <i>Laboratoriums Medizin</i> , <b>2003</b> , 27, 211-221		
29	Phenotypic and genotypic analysis of thiopurine s-methyltransferase polymorphism in the bulgarian population. <i>Therapeutic Drug Monitoring</i> , <b>2003</b> , 25, 631-6	3.2	40
28	Acyl glucuronide drug metabolites: toxicological and analytical implications. <i>Therapeutic Drug Monitoring</i> , <b>2003</b> , 25, 1-16	3.2	226
27	Determination of thiopurine methyltransferase phenotype in isolated human erythrocytes using a new simple nonradioactive HPLC method. <i>Therapeutic Drug Monitoring</i> , <b>2003</b> , 25, 637-44	3.2	26
26	Erosive enterocolitis in mycophenolate mofetil-treated renal-transplant recipients with persistent afebrile diarrhea. <i>Transplantation</i> , <b>2003</b> , 75, 665-72	1.8	111

25	Therapie mit Thiopurin-Medikamenten ¶TDM und Pharmakogenomik der TPMT. <i>Laboratoriums Medizin</i> , <b>2003</b> , 27, 211-221		
24	Differences in nucleotide hydrolysis contribute to the differences between erythrocyte 6-thioguanine nucleotide concentrations determined by two widely used methods. <i>Clinical Chemistry</i> , <b>2003</b> , 49, 260-8	5.5	82
23	A new acute inflammatory syndrome related to the introduction of mycophenolate mofetil in patients with Wegener's granulomatosis. <i>Nephrology Dialysis Transplantation</i> , <b>2002</b> , 17, 923-6	4.3	33
22	Atypical pharmacokinetics and metabolism of mycophenolic acid in a young kidney transplant recipient with impaired renal function. <i>Therapeutic Drug Monitoring</i> , <b>2002</b> , 24, 438-43	3.2	5
21	Pharmacokinetics and protein adduct formation of the pharmacologically active acyl glucuronide metabolite of mycophenolic acid in pediatric renal transplant recipients. <i>Therapeutic Drug Monitoring</i> , <b>2002</b> , 24, 390-9	3.2	88
20	Comparison of the Emit Immunoassay with HPLC for Therapeutic Drug Monitoring of Mycophenolic Acid in Pediatric Renal-Transplant Recipients on Mycophenolate Mofetil Therapy. <i>Clinical Chemistry</i> , <b>2002</b> , 48, 517-525	5.5	102
19	The pharmacokinetic-pharmacodynamic relationship for total and free mycophenolic Acid in pediatric renal transplant recipients: a report of the german study group on mycophenolate mofetil therapy. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2002</b> , 13, 759-768	12.7	192
18	Preliminary report on the effect of xenoperfusion with human blood on cyclosporin A metabolism and cytochrome-P-4503A4-mRNA expression in a pig liver perfusion model. <i>Clinical Biochemistry</i> , <b>2001</b> , 34, 53-7	3.5	2
17	Rapid and Sensitive Liquid Chromatography¶ tandem Mass Spectrometry Method for Determination of Monoethylglycinexylidide. <i>Clinical Chemistry</i> , <b>2001</b> , 47, 1853-1856	5.5	4
16	Quantification of Mycophenolic Acid in Plasma Samples Collected during and Immediately after Intravenous Administration of Mycophenolate Mofetil. <i>Clinical Chemistry</i> , <b>2001</b> , 47, 1485-1488	5.5	20
15	Effect of cyclosporine withdrawal on mycophenolic acid pharmacokinetics in kidney transplant recipients with deteriorating renal function: preliminary report. <i>Therapeutic Drug Monitoring</i> , <b>2001</b> , 23, 717-21	3.2	66
14	Induction of cytokine release by the acyl glucuronide of mycophenolic acid: a link to side effects?. <i>Clinical Biochemistry</i> , <b>2000</b> , 33, 107-13	3.5	131
13	Mycophenolate mofetil in stem cell transplant patients in relation to plasma level of active metabolite. <i>Clinical Biochemistry</i> , <b>2000</b> , 33, 203-8	3.5	26
12	Determination of the Acyl Glucuronide Metabolite of Mycophenolic Acid in Human Plasma by HPLC and Emit. <i>Clinical Chemistry</i> , <b>2000</b> , 46, 365-372	5.5	136
11	The monoethylglycinexylidide (MEGX) test as a marker of hepatic dysfunction in septic patients with pneumonia. <i>Clinical Chemistry and Laboratory Medicine</i> , <b>2000</b> , 38, 1125-8	5.9	10
10	Pharmacokinetic and metabolic investigations of mycophenolic acid in pediatric patients after renal transplantation: implications for therapeutic drug monitoring. German Study Group on Mycophenolate Mofetil Therapy in Pediatric Renal Transplant Recipients. <i>Therapeutic Drug Monitoring</i> , <b>2000</b> , 22, 20-6	3.2	157
9	Evaluation of an immunoassay for mycophenolic acid. <i>Therapeutic Drug Monitoring</i> , <b>2000</b> , 22, 141-2	3.2	9
8	Mycophenolate mofetil decreases endothelial prostaglandin E2 in response to allogeneic T cells or cytokines. <i>Transplantation</i> , <b>2000</b> , 69, 1977-81	1.8	8

7	Stability of Mycophenolic Acid and Mycophenolic Acid Glucuronide in Human Plasma. <i>Clinical Chemistry</i> , <b>1999</b> , 45, 127-129	5.5	17
6	Identification of a Pharmacologically Active Metabolite of Mycophenolic Acid in Plasma of Transplant Recipients Treated with Mycophenolate Mofetil. <i>Clinical Chemistry</i> , <b>1999</b> , 45, 419-422	5.5	126
5	Identification of glucoside and carboxyl-linked glucuronide conjugates of mycophenolic acid in plasma of transplant recipients treated with mycophenolate mofetil. <i>British Journal of Pharmacology</i> , <b>1999</b> , 126, 1075-82	8.6	168
4	Area under the plasma concentration-time curve for total, but not for free, mycophenolic acid increases in the stable phase after renal transplantation: a longitudinal study in pediatric patients. German Study Group on Mycophenolate Mofetil Therapy in Pediatric Renal Transplant Recipients. <i>Therapeutic Drug Monitoring</i> , <b>1999</b> , 21, 498-506	3.2	92
3	Monoethylglycinexylidide (MEGX) liver function test is not compromised by 3-hydroxy MEGX in humans. <i>Hepatology</i> , <b>1998</b> , 28, 1439-40	11.2	4
2	Determination of monoethylglycinexylidide by fluorescence polarization immunoassay in highly icteric serum samples: modified precipitation procedure and HPLC compared. <i>Clinical Chemistry</i> , <b>1998</b> , 44, 1269-1274	5.5	8
1	Simultaneous determination of mycophenolic acid and its glucuronide in human plasma using a simple high-performance liquid chromatography procedure. <i>Clinical Chemistry</i> , <b>1998</b> , 44, 1481-1488	5.5	110